09 February 2012
("Instem", the "Company" or the "Group")
Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, announces that Chief Financial Officer, Nigel Goldsmith has been granted options over 20,000 ordinary shares of 10p each ("Ordinary Shares"). These options become exercisable after a period of three years subject to market based performance criteria, pursuant to the rules of the Company’s All Staff LTIP and approved by the Remuneration Committee on 7 February 2012. The exercise price of 176p represents the closing mid-market price of the Ordinary Shares as at 07 February 2012.
For further information, please contact:
|Phil Reason, CEO||+44 (0) 1785 825600|
|Nigel Goldsmith, CFO|
|N+1 Singer (Nominated Adviser & Broker)||+44 (0) 20 7496 3000|
|Wallbrook Financial PR||Tel: +44 (0) 20 7933 8000|
|Paul Cornelius||or firstname.lastname@example.org|
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.